L-type Ca 2+ channels (LTCC) play a crucial role in cardiac excitation-contraction coupling.
Introduction
Despite recently advanced medical therapies, heart failure is one of the leading risks of death in developed nations (Go et al., 2013) . Thus, development of medical treatment based on further understanding of the pathophysiology of heart failure is required to improve the quality of life of patients with heart failure. Maladaptive remodeling of ventricular excitation-contraction (EC) coupling caused by such as chronic -adrenergic receptor stimulation, and activation of the reninangiotensin-aldosterone system plays a predominant role in an impaired cardiac function in heart failure (Mann, 2008; Osadchii, 2007; Rockman et al., 2002) . The underlying primary defect is a decrease in sarcoplasmic reticulum (SR) Ca 2+ content due to decreased activity and/or expression of SR Ca 2+ -ATPase 2, increased expression of sarcolemmal Na + /Ca 2+ exchangers and diastolic Ca 2+ leak from the SR via ryanodine receptors (Bers, 2008) . L-type Ca 2+ channel (LTCC) currents play a crucial role in cardiac EC coupling (McDonald et al., 1994) . In most cardiac hypertrophy and failure, whole-cell LTCC current density is reported not to change markedly (Bers, 2008; Mukherjee and Spinale, 1998) . However, we previously found for the first time that basal t-tubular (TT) LTCC activity was halved by activation of protein phosphatase (PP)2A whereas basal surface sarcolemmal (SS) LTCC activity was doubled by inhibition of PP1 in failing ventricular myocytes of mice chronically treated with isoproterenol (Horiuchi-Hirose et al., 2011; Kashihara et al., 2012) . Because Gi/o proteins are known to activate PP2A (Herzig et al., 1995; Ke et al., 2004; Liu and Hofmann, 2003) and suppress PP1 in cardiac myocytes (Zhu et al., 2008) , we examined the effect on isoproterenol-treated mice of pertussis toxin, a selective inhibitor of the coupling between G protein-coupled receptors and Gi/o proteins (Kashihara et al., 2012) . Pertussis toxin significantly increased basal TT LTCC activity, decreased basal SS LTCC activity and increased cardiac contractility independently of protein kinase A in isoproterenol-treated mice.
In this study, we sought to identify the G protein-coupled receptors that lead to abnormal LTCC activity and cardiac dysfunction in heart failure. In the heart, M2-muscarinic and A1-adenosine receptors are the principal G protein-coupled receptors coupled with Gi/o proteins. Moreover, the phosphorylation of 2-adrenergic receptors by protein kinase A or G protein-coupled receptor kinase, which are expected to occur in heart failure, switches their coupling from Gs to Gi (Daaka et al., 1997; Liu et al., 2009) ; therefore, we examined whether any of these three types of receptors are involved in the abnormalities in isoproterenol-treated mice with a selective antagonist for each receptor.
In the present study, we found that chronic activation of 2-adrenergic and M2-muscarinic, but not A1-adenosine receptors decreases cardiac contractile function at least partially by decreasing basal TT LTCC activity in heart failure. Therefore, antagonists of 2-adrenergic and M2-muscarinic receptors can be good adjuncts to 1-adrenergic receptor antagonists in the treatment of heart failure. the inhibition of 2-adrenergic, M2-muscarinic and A1-adenosine receptors on isoproterenol-induced cardiac hypertrophy and failure, mice were treated with 0.5 mg/kg/day ICI118,551, 3 mg/kg/day atropine or 1 mg/kg/day DPCPX along with isoproterenol. ICI118,551 and atropine were applied to mice through osmotic minipumps (model 1004; Alzet, Cupertino, CA, USA) whereas DPCPX was applied daily intraperitoneally because it is too hydrophobic to be used with osmotic minipumps.
The dose of ICI118,551 (0.5 mg/kg/day) was the maximum applicable to mice with the pump. The blood concentration of ICI118,551 in mice applied with this dose of the agent was 0.54 ± 0.07 nM whereas the pA2 value of this agent for 1 and 2-adrenergic receptors is 7.17 and 9.26, respectively.
The dose of atropine was determined according to previous reports (Jumrussirikul et al., 1998; Uechi et al., 1998) . In pilot studies, mice injected with 1, 3 or 10 mg/kg/day of atropine along with 6 mg/kg/day isoproterenol exhibited the fractional shortening of 32.7 ± 1.9, 36.4 ± 1.0, 35.0 ± 1.4%, respectively. Thus, we used the maximum effective dose of atropine (i.e. 3 mg/kg/day). The dose of DPCPX was determined according to a previous report (Koeppen et al., 2009 ). The half maximum inhibitory dose of intravenously applied N6-cyclopentyladenosine, a selective A1 adenosine receptor agonist in causing negative chronotropic effect was 7.09 and 226 g/kg in mice injected with saline or 1 mg/kg/day DPCPX. Pumps were implanted under pentobarbital sodium (30 mg/kg) anesthesia administered intraperitoneally on Day -1. These antagonists were applied to mice from Day -1 to 21, whereas isoproterenol was applied from Day 0 to 21.
All animals were used for experiments on Day 22. Animals were sacrificed by sodium pentobarbital (30 mg/kg) anesthesia administrated intraperitoneally. The hearts and lungs were excised from the animals, rinsed in ice-cold modified Tyrode solution containing (in mmol/l): NaCl, 136.5; KCl, 5.4; CaCl2, 1.8; MgCl2, 0.53; HEPES (Dojindo Laboratories, Kumamoto, Japan), 5.5; and glucose, 5.5 (pH = 7.4 with NaOH) and weighed. Because the body weight of all groups of mice treated with drugs was significantly higher than that of saline-treated mice (Horiuchi-Hirose et al., 2011) , the heart weight (HW; in mg) and lung weight (LW; in mg) were normalized to the tibial length (TL; in mm), which was not significantly different among the five groups of mice (i.e. HW/TL and LW/TL).
Gross and histological evaluation of hearts
The morphology of the heart was evaluated as previously described (Horiuchi-Hirose et al., 2011) . Briefly, the hearts were fixed in 20% phosphate-buffered formalin at room temperature for 24 h and cut transversely to obtain ventricular cross sections. The tissues were then embedded in paraffin and cut into 4-m thick slices. Histological sections were stained with hematoxylin-eosin and examined with a light microscope (BX-51; Olympus Corp., Tokyo, Japan). Wall thickness and the chamber diameter of the left ventricle were measured with an objective micrometer as the scale on digital microscopic images taken from histological sections.
Measurement of heart rate (HR) and mean systemic blood pressure (MBP).
HR and MBP in conscious, warmed and restrained mice were measured by the tail-cuff method with a programmable sphygmomanometer (BP-98A; Softron, Tokyo, Japan) once a week between Day -1 and 22. Mice were restrained for 3 min with a temperature-controlled warming holder (37°C) before these measurements. Each estimation was the average of three records taken at 1 min intervals. These measurements were performed 20 h after the isoproterenol injection.
Ultrasound cardiography
Cardiac function was assessed with ultrasound cardiography (GE Yokogawa Medical System K.K., Tokyo, Japan) in anesthetized mice as previously described (Horiuchi-Hirose et al., 2011) . Briefly, hearts were viewed at the level of the papillary muscles in the short axis. On M-mode tracings, the average of three consecutive beats was used to measure the following parameters: left ventricular (LV) end-diastolic diameter (EDD); LV end-systolic diameter (ESD); and fractional shortening (FS), calculated as (EDD − ESD)/EDD × 100%.
Cardiac catheterization.
Under 2,2,2-tribromoethanol (250 mg/kg) anesthesia administrated intraperitoneally, a micro-tipped pressure catheter transducer (model 420 LP; Samba Sensor, Gothenburg, Sweden) was inserted into the right carotid artery and advanced into the LV cavity. After stabilization for 5 min, the signal was continuously recorded with a Samba 201 system (Samba Sensor) coupled with a PowerLab system (Chart4; ADInstruments, Dunedin, New Zealand), stored and displayed on a computer. LV preload was assessed by end-diastolic pressure (LVEDP; in mmHg); contractility, by dP/dtmax (in mmHg/s); and relaxation, by dP/dtmin (in mmHg/s).
Isolation of cardiac myocytes.
Ventricular myocytes were enzymatically isolated as previously described (Horiuchi-Hirose et al., 2011) . Briefly, the heart mounted on a Langendorff apparatus was digested with nominally Ca 2+ -free Tyrode solution containing 0.80 mg/ml collagenase, 0.06 mg/ml protease (Sigma-Aldrich, Inc.), 1.20 mg/ml hyaluronidase (Sigma-Aldrich, Inc.), 0.03 mg/ml DNase I (F.
Hoffmann-La Roche Ltd., Basel, Switzerland) and 0.50 mg/ml bovine serum albumin at 37°C for 2 min. Isolated ventricular myocytes were suspended in Ca 2+ -free Tyrode solution containing 1 mg/ml bovine serum albumin at room temperature, and the Ca 2+ concentration was gradually increased to 1.8 mmol/l.
Detubulation
Detubulation of isolated ventricular myocytes was carried out with osmotic shock as previously described (Horiuchi-Hirose et al., 2011; Kawai et al., 1999) . Briefly, myocytes were treated with modified Tyrode solution containing formamide (1.5 mol/l) for 15 min and returned to the modified Tyrode solution. A membrane-staining dye, di-8-ANEPPS clearly stained t-tubules in non-detubulated but barely in detubulated myocytes (Horiuchi-Hirose et al., 2011) , suggesting that detubulation detached the t-tubular invaginations from the surface sarcolemma because hydrophobic di-8-ANEPPS could stain the t-tubules that were occluded yet connected to the sarcolemma. In different experiments, detubulation significantly reduced cell membrane capacitance (Table 1) , indicating that intra-t-tubular space was electrically disconnected from extracellular space. Taken together, it is likely that t-tubular LTCC currents were not measured in the whole-cell configuration in detubulated myocytes.
Electrophysiology
The current of isolated ventricular myocytes was studied in the whole-cell configuration of the patch-clamp technique at 35-37°C with a patch-clamp amplifier (EPC8; HEKA Instruments Inc., Bellmore, NY, USA) as previously described (Horiuchi-Hirose et al., 2011) . Series resistance was always kept <7 M and was routinely compensated using an amplifier by ~75%. This resulted in a voltage drop in series resistance of <3.5 mV in the presence of 2 nA membrane currents. LTCC currents were measured with pipette solution containing (in mmol/l): D-glutamate, 90; N-methyl-D(-)-glucamine, 10; MgCl2, 5; tetraethylammonium chloride, 20; EGTA, 10; HEPES, 20; and ATP 3 (pH = 7.3 with CsOH). The bathing solution contained (in mmol/l): N-methyl-D(-)-glucamine, 150; CsCl, 5.4; CaCl2, 2; MgCl2, 1.2; 4-aminopyridine, 2; HEPES, 5; and glucose, 5.5 (pH = 7.4 with HCl). The membrane potential was stepped from -90 mV to -50 mV for 200 msec and then for 500 msec to potentials between -110 and +70 mV with a 10 mV increment every 5 sec. LTCC currents were isolated as the current inhibited by Cd 2+ (100 mol/l) plus nifedipine (10 mol/l) (Yamada et against the membrane potential.
To assess SS and TT LTCC current densities, the peak LTCC current amplitude at 0 mV and the membrane capacitance were measured in non-detubulated and detubulated myocytes (Table   1 ). SS and TT LTCC current densities were calculated from these values as previously described (Horiuchi-Hirose et al., 2011) . Briefly, the LTCC current density in SS and TT (DSS and DTT, respectively) was calculated with the following equations:
, where IN and ID are the peak LTCC current amplitude at 0 mV of non-detubulated and detubulated myocytes, respectively; CN and CD, the membrane capacitance of non-detubulated and detubulated myocytes, respectively; and , fraction of TT membranes remaining in detubulated myocytes.  was estimated as 0.17 from binary image analysis of detubulated myocytes stained with di-8-ANEPPS.
Because non-detubulated and detubulated myocytes were different groups of myocytes, the above calculation was carried out with the mean membrane capacitance and current amplitude of each group.
The liquid junction potential of the pipette solution in relation to the modified Tyrode solution was -10 mV and taken into consideration throughout this study. 
Results
3.1 Effect of inhibition of Gi/o protein-coupled 2-adrenergic, M2-muscarinic and A1-adenosine receptors on cardiac hypertrophy and failure in mice chronically treated with isoproterenol.
We first examined whether inhibition of cardiac major Gi/o-coupled receptors (2adrenergic, M2-musucarinic, and A1-adenosine receptors) with antagonists ameliorated the cardiac hypertrophy and failure of isoproterenol-treated mice. Namely, mice were treated with saline alone, isoproterenol alone, isoproterenol plus ICI118,551, isoproterenol plus atropine, or isoproterenol plus DPCPX. Mice treated with these drugs showed cardiac hypertrophy and dilation of ventricular chambers compared with those treated with saline ( Fig. 1A) . Although the left ventricular wall thickness (LVWT) was comparable in all groups, the left ventricular chamber diameter (LVCD) and HW/TL were significantly higher in mice treated with the drugs than those treated with saline ( Fig.   1B ), indicating that neither 2-adrenergic, M2-musucarinic, nor A1-adenosine receptors contributed to isoproterenol-induced cardiac hypertrophy. LW/TL was also significantly higher in mice treated with the drugs than those treated with saline; however, LW/TL of mice treated with isoproterenol plus ICI118,551 or atropine was significantly lower than that of mice treated with isoproterenol alone (Fig. 1B) , indicating that ICI118,551 and atropine ameliorated the congestive heart failure caused by isoproterenol. Table 2 summarizes alterations in the HR and MBP during the treatment of mice with saline or the drugs. HR of mice treated with isoproterenol alone progressively decreased as compared with those treated with saline, which was not attenuated by ICI118,551, atropine or DPCPX, most likely as a consequence of downregulation of 1-adrenergic receptors. MBP also progressively decreased in mice treated with the drugs as compared with those treated with saline;
however, MBP of mice treated with isoproterenol plus ICI118,551 or atropine was significantly higher than that of mice treated with isoproterenol alone, indicating that the effect of ICI118,551 and atropine on pulmonary edema was not due to their effect on the afterload of the heart.
M-mode ultrasound cardiogram showed that mice treated with isoproterenol alone exhibited increased end-diastolic and -systolic left ventricular diameters and decreased wall motion as compared with saline-treated mice as previously reported ( Fig. 2A ) (Horiuchi-Hirose et al., 2011) .
Mice treated with isoproterenol plus ICI118,551 or atropine exhibited smaller end-systolic left ventricular diameters and better wall motion than those treated with isoproterenol alone. These parameters of mice treated with isoproterenol plus DPCPX were comparable with those of mice treated with isoproterenol alone. Calculated fractional shortening (FS) of mice treated with isoproterenol plus ICI118,551 or atropine was significantly lower than that of mice treated with saline but significantly higher than that of mice treated with isoproterenol alone (Fig. 2B) . FS was greatly decreased in mice treated with isoproterenol alone or isoproterenol plus DPCPX as compared with those treated with saline.
Hemodynamic assessment with catheterization showed that mice treated with the drugs exhibited significantly higher LVEDP and significantly smaller dP/dtmax and dP/dtmin than salinetreated mice (Fig. 3A, B and C) (Horiuchi-Hirose et al., 2011) . However, mice treated with isoproterenol plus ICI118,551 or atropine exhibited significantly higher dP/dtmax and dP/dtmin and lower LVEDP than those treated with isoproterenol alone. These parameters of mice treated with isoproterenol plus DPCPX were comparable with those of mice treated with isoproterenol alone; therefore, 2-adrenergic and M2-muscarinic, but not A1-adenosine receptors were involved in the cardiac dysfunction of isoproterenol-treated mice.
3.2 Effect of inhibition of Gi/o protein-coupled 2-adrenergic, M2-muscarinic and A1-adenosin receptors on the L-type Ca 2+ channel current density in mice chronically treated with isoproterenol.
We previously demonstrated that chronic G protein-coupled receptor-mediated activation of Gi/o decreased cardiac contractility at least partially by decreasing TT LTCC current density in isoproterenol-treated mice (Kashihara et al., 2012) . We therefore assessed whether inhibition of 2adrenergic, M2-muscarinic, and A1-adenosine receptors normalized LTCC current density in myocytes of mice chronically treated with isoproterenol. Figure 4A (solid lines) shows representative whole-cell LTCC currents of myocytes of each group of mice in response to depolarization to 0 mV from the prepulse of -50 mV. To separately assess SS and TT LTCC current densities, we measured LTCC currents in ventricular myocytes with detubulation, a procedure to acutely occlude TT in isolated ventricular myocytes (Horiuchi-Hirose et al., 2011; Kawai et al., 1999) . As shown in Fig. 4A (broken lines) , detubulation substantially reduced LTCC current amplitude in all groups of myocytes. Figure 4B shows the pooled data of the peak current-voltage relationships. Detubulation reduced the LTCC current amplitude by 62% in myocytes of saline-treated mice but by only 30% in those of isoproterenol-treated mice (Fig. 4A and B) , indicating that TT LTCC currents were decreased in isoproterenol vs. saline-treated mice. On the other hand, detubulation reduced the LTCC current amplitude by 60% in myocytes of mice treated with isoproterenol plus ICI118,551; by 57%, isoproterenol plus atropine; and by 35%, isoproterenol plus DPCPX. Thus, inhibition of 2adrenergic and M2-muscarinic, but not A1-adenosine receptors may have attenuated the decreased TT LTCC current density found in myocytes of mice treated with isoproterenol.
From the peak LTCC current amplitude at 0 mV and the membrane capacitance of nondetubulated and detubulated myocytes (Table 1) , we could assess the LTCC current density in SS and TT membrane compartments (Horiuchi-Hirose et al., 2011). There were no significant differences in whole-cell (WC) LTCC current density in each group of myocytes (Fig. 4C ). In myocytes of saline-treated mice, there was ~5 times higher LTCC current density in the TT membrane than in the SS membrane (Horiuchi-Hirose et al., 2011) . In myocytes of isoproterenoltreated mice, there were significantly higher SS and lower TT LTCC current densities than in myocytes of saline-treated mice. Notably, myocytes of mice treated with isoproterenol plus ICI118,551 or atropine but not DPCPX showed significantly lower SS and higher TT LTCC current densities than those of mice treated with isoproterenol alone. The LTCC current densities in myocytes of mice treated with isoproterenol plus ICI118,551 and atropine were similar to those of myocytes of saline-treated mice; therefore, 2-adrenergic and M2-muscarinic receptors may have induced cardiac dysfunction in isoproterenol-treated mice at least partially by decreasing TT LTCC activity.
Effect of inhibition of protein phosphatases on the L-type Ca 2+ channel current density in each group of mice.
We previously reported that in isoproterenol-treated mice, SS LTCC current density is increased due to Gi/o-mediated suppression of PP1 whereas TT LTCC current density is decreased due to Gi/o-mediated activation of PP2A (Horiuchi-Hirose et al., 2011; Kashihara et al., 2012) . Thus, we finally examined whether ICI118,551 and atropine normalized SS and TT LTCC current densities by ameliorating the abnormal PP activities. Figure 5A shows the WC, SS and TT LTCC current densities in each group of mice in the presence of okadaic acid (OA) (1 M), a PP1 and PP2A inhibitor, where the difference in SS and TT LTCC densities among groups was abolished. This indicates that isoproterenol caused the abnormal LTCC densities whereas ICI118,551 and atropine, but not DPCPX normalized the LTCC densities by modifying PP1 and/or 2A. Figure 5B shows 
Discussion
In heart failure, chronic and excessive -adrenergic receptor stimulation causes remodeling of the myocardium and aggravates cardiac function (Osadchii, 2007; Rockman et al., 2002) . This concept is the theoretical basis for the treatment of heart failure with -adrenergic antagonists. In experiments, transgenic overexpression of 1-adrenergic receptors in the murine heart causes dilated cardiomyopathy (Engelhardt et al., 1999) . We also found that metoprolol, a selective 1-adrenergic antagonist, almost completely prevented cardiac hypertrophy and failure of isoproterenol-treated mice (data not shown), indicating that excessive stimulation of 1-adrenergic receptors is the primary cause of myocardial remodeling in isoproterenol-treated mice (Osadchii, 2007; Xiao et al., 2006) .
However, we also previously found that chronic administration of pertussis toxin significantly improved the cardiac function of isoproterenol-treated mice, indicating that Gi/o chronically activated by some G protein-coupled receptors participate in the cardiac dysfunction of isoproterenol-treated mice (Kashihara et al., 2012) . Consistent with this observation, it is reported that the increased activity of Gi/o suppresses cardiac function in heart failure (El-Armouche et al., 2003) . In the present study, we sought to identify Gi/o protein-coupled receptors contributing to the cardiac dysfunction of isoproterenol-treated mice. Compared with mice treated with isoproterenol alone, mice treated with isoproterenol plus ICI118,551 or atropine, but not DPCPX showed significantly lower LW/TL (Fig.   1B ) and better hemodynamic parameters (i.e. higher FS (Fig. 2B) , lower LVEDP, and higher dP/dtmax and dP/dtmin ( Fig. 3B and C) ). In addition, myocytes of mice treated with isoproterenol plus ICI118,551 or atropine, but not DPCPX exhibited significantly higher TT and lower SS LTCC current densities than those of mice treated with isoproterenol alone (Fig. 4C ) due to normalization of PP activities (Fig. 5) . Thus, chronic activation of 2-adrenergic and M2-muscarinic, but not A1adenosine receptors may cause cardiac dysfunction at least partially by decreasing basal TT LTCC activity in isoproterenol-treated mice. It is, however, necessary to confirm the present finding in more clinically relevant models of heart failure, such as those induced by pressure/volume overload or myocardial infarction, in future.
It is uncertain whether Gi/o was activated by ligand-independent (i.e. basal) or -dependent activity of 2-adrenergic and M2-muscarinic receptors in isoproterenol-treated mice because ICI118,551 and atropine exert inverse agonism under some conditions (Nelson et al., 2006; Zhou et al., 1999) . In animal models of heart failure and patients with idiopathic dilated cardiomyopathy, the expression level of M2-muscaric receptors is increased (Le Guludec et al., 1997; Vatner et al., 1996) .
It is also known that 2-adrenergic receptors become more efficiently coupled with Gi/o in a failing than normal heart (Daaka et al., 1997; Liu et al., 2009; Paur et al.) . These changes of M2-muscarinic and 2-adrenergic receptors chronically increase Gi/o activity independently of their ligands. Indeed, we found that abnormal LTCC activities persisted at least for several hours in isolated myocytes of isoproterenol-treated mice in the absence of any G protein-coupled receptor agonists (Horiuchi-and M2-muscarinic receptors were activated by their ligands in vivo. Although isoproterenol administrated to mice must have stimulated 2-adrenergic receptors, adrenaline secreted from the adrenal medulla would also have activated 2-adrenergic receptors because its plasma concentration increases in heart failure (Kaye et al., 1995; Paur et al.) . It is somewhat surprising that acetylcholine acting on M2-muscarinic receptors worsens heart failure because many experimental studies have demonstrated that vagal stimulation has beneficial effects on heart failure (Kishi, 2012) . Recently, Kanazawa et al. reported that the cardiac sympathetic nervous system exhibits cholinergic transdifferentiation in heart failure (Kanazawa et al., 2010) . Thus, one possibility is that such aberrant acetylcholine might cause deteriorating effects on failing cardiac myocytes. Probably, both ligand-independent and -dependent activities of 2-adrenergic and M2-muscarinic receptors cause abnormal LTCC activities and cardiac function under excessive 1-adrenergic stimulation in heart failure.
Gi/o inhibits adenylyl cyclase (Sunahara et al., 1996) . Thus, ICI118,551 and atropine might have improved cardiac function by increasing cAMP concentration in myocytes; however, neither mice treated with isoproterenol plus ICI118,551 nor atropine exhibited significantly higher HR than mice treated with isoproterenol alone (Table 2) , contrary to this speculation. Moreover, we previously found that a selective protein kinase A inhibitor, H-89 did not affect SS or TT LTCC activity in ventricular myocytes of mice chronically treated with isoproterenol plus pertussis toxin, indicating that the chronic inhibition of Gi/o did not significantly increase cAMP concentration in cardiac myocytes (Kashihara et al., 2012) . We propose that ICI118,551 and atropine increased cardiac function of isoproterenol-treated mice by normalizing the abnormal effects of PPs on basal LT CC activity independently of protein kinase A (Fig. 5 ). ICI118,551 and atropine each separately substantially reversed the effect of isoproterenol on many parameters measured in this study: i.e. these drug effects were not additive. This was probably because 2-adrenergic and M2-muscarinic receptors shared Gi/o proteins and PPs as a common pathway. Although Liu and Hoffmann reported that activation of A1-adenosine receptors lead to PP2A-induced dephosphorylation of phospholamban and troponin T in cardiac myocytes, we did not see significant effects of DPCPX on LTCC activity (Liu and Hofmann, 2003) . PP2A has many different subunit compositions and, depending on the composition, different subcellular localization and different regulation (Janssens and Goris, 2001) . Thus, we speculate that PP2A associated with LTCC may not be regulated by A1adenosine receptors in cardiac myocytes.
Conclusion
To summarize, for the first time, we found that chronic activation of Gi/o through 2adrenergic and M2-muscarinic, but not A1-adenosine receptors compromises cardiac contractility at least partially by altering basal TT LTCC activity in heart failure. Thus, selective antagonists of 2adrenergic and M2-muscarinic receptors may be useful in the treatment of chronic heart failure with excessive -adrenergic stimulation; however, it is known that increased Gi/o activity is not only harmful but also protective of a failing heart because it prevents excessive Gs/cAMP/protein kinase A stimulation. Therefore, it would be desirous to use these antagonists in heart failure in conjunction with -adrenergic blockers that suppress Gs activity. Values are the mean ± S.E.M. N = 6 for all groups. CONT, control; ISO, isoproterenol; ICI, ICI118,551; ATR, atropine. a P < 0.05 vs. CONT; b P < 0.05 vs. 
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